|Universal blue circle symbol for diabetes|
|Duration||Remission may occur, but diabetes is often life-long|
|Causes||Insulin insufficiency or gradual resistance|
|Frequency||463 million (8.8%)|
|Deaths||4.2 million (2019)|
Diabetes, also known as diabetes mellitus, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body not responding properly to the insulin produced. Diabetes, if left untreated, leads to many health complications. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths per year.
There is no widely-accepted cure for most cases of diabetes. The most common treatment for type 1 diabetes is insulin replacement therapy (insulin injections). Anti-diabetic medications such as metformin and semaglutide, as well as lifestyle modifications, can be used to prevent or respond to type 2 diabetes. Gestational diabetes normally resolves shortly after delivery.
As of 2019, an estimated 463 million people had diabetes worldwide accounting for 8.8% of the adult population. Type 2 diabetes makes up about 90% of all diabetes cases. The prevalence of the disease continues to increase, most dramatically in low- and middle-income nations. Rates are similar in women and men, with diabetes being the 7th-leading cause of death globally. The global expenditure on diabetes-related healthcare is an estimated USD760 billion a year.
Signs and symptoms
The classic symptoms of untreated diabetes are unintended weight loss, polyuria (increased urination), polydipsia (increased thirst), and polyphagia (increased hunger). Symptoms may develop rapidly (weeks or months) in type 1 diabetes, while they usually develop much more slowly and may be subtle or absent in type 2 diabetes.
Several other signs and symptoms can mark the onset of diabetes although they are not specific to the disease. In addition to the known symptoms listed above, they include blurred vision, headache, fatigue, slow healing of cuts, and itchy skin. Prolonged high blood glucose can cause glucose absorption in the lens of the eye, which leads to changes in its shape, resulting in vision changes. Long-term vision loss can also be caused by diabetic retinopathy. A number of skin rashes that can occur in diabetes are collectively known as diabetic dermadromes.
People with diabetes (usually but not exclusively in type 1 diabetes) may also experience diabetic ketoacidosis (DKA), a metabolic disturbance characterized by nausea, vomiting and abdominal pain, the smell of acetone on the breath, deep breathing known as Kussmaul breathing, and in severe cases a decreased level of consciousness. DKA requires emergency treatment in hospital. A rarer but more dangerous condition is hyperosmolar hyperglycemic state (HHS), which is more common in type 2 diabetes and is mainly the result of dehydration caused by high blood sugars.
Treatment-related low blood sugar (hypoglycemia) is common in people with type 1 and also type 2 diabetes depending on the medication being used. Most cases are mild and are not considered medical emergencies. Effects can range from feelings of unease, sweating, trembling, and increased appetite in mild cases to more serious effects such as confusion, changes in behavior such as aggressiveness, seizures, unconsciousness, and rarely permanent brain damage or death in severe cases. Rapid breathing, sweating, and cold, pale skin are characteristic of low blood sugar but not definitive. Mild to moderate cases are self-treated by eating or drinking something high in rapidly absorbed carbohydrates. Severe cases can lead to unconsciousness and must be treated with intravenous glucose or injections with glucagon.
All forms of diabetes increase the risk of long-term complications. These typically develop after many years (10–20) but may be the first symptom in those who have otherwise not received a diagnosis before that time.
The major long-term complications relate to damage to blood vessels. Diabetes doubles the risk of cardiovascular disease and about 75% of deaths in people with diabetes are due to coronary artery disease. Other macrovascular diseases include stroke, and peripheral artery disease. These complications are also a strong risk factor for severe COVID-19 illness.
The primary complications of diabetes due to damage in small blood vessels include damage to the eyes, kidneys, and nerves. Damage to the eyes, known as diabetic retinopathy, is caused by damage to the blood vessels in the retina of the eye, and can result in gradual vision loss and eventual blindness. Diabetes also increases the risk of having glaucoma, cataracts, and other eye problems. It is recommended that people with diabetes visit an optometrist or ophthalmologist once a year. Damage to the kidneys, known as diabetic nephropathy, can lead to tissue scarring, urine protein loss, and eventually chronic kidney disease, sometimes requiring dialysis or kidney transplantation. Damage to the nerves of the body, known as diabetic neuropathy, is the most common complication of diabetes. The symptoms can include numbness, tingling, sudomotor dysfunction, pain, and altered pain sensation, which can lead to damage to the skin. Diabetes-related foot problems (such as diabetic foot ulcers) may occur, and can be difficult to treat, occasionally requiring amputation. Additionally, proximal diabetic neuropathy causes painful muscle atrophy and weakness.
There is a link between cognitive deficit and diabetes. Compared to those without diabetes, those with the disease have a 1.2 to 1.5-fold greater rate of decline in cognitive function. Having diabetes, especially when on insulin, increases the risk of falls in older people.
|Feature||Type 1 diabetes||Type 2 diabetes|
|Age at onset||Mostly in children||Mostly in adults|
|Body size||Thin or normal||Often obese|
|Endogenous insulin||Low or absent||Normal, decreased|
|Heritability||0.69 to 0.88||0.47 to 0.77|
|<2 per 1,000||~6% (men), ~5% (women)|
Diabetes mellitus is classified into six categories: type 1 diabetes, type 2 diabetes, hybrid forms of diabetes, hyperglycemia first detected during pregnancy, "unclassified diabetes", and "other specific types". "Hybrid forms of diabetes" include slowly evolving, immune-mediated diabetes of adults and ketosis-prone type 2 diabetes. "Hyperglycemia first detected during pregnancy" includes gestational diabetes mellitus and diabetes mellitus in pregnancy (type 1 or type 2 diabetes first diagnosed during pregnancy). The "other specific types" are a collection of a few dozen individual causes. Diabetes is a more variable disease than once thought and people may have combinations of forms.
Type 1 diabetes is characterized by loss of the insulin-producing beta cells of the pancreatic islets, leading to insulin deficiency. This type can be further classified as immune-mediated or idiopathic. The majority of type 1 diabetes is of an immune-mediated nature, in which a T cell-mediated autoimmune attack leads to the loss of beta cells and thus insulin. It causes approximately 10% of diabetes mellitus cases in North America and Europe. Most affected people are otherwise healthy and of a healthy weight when onset occurs. Sensitivity and responsiveness to insulin are usually normal, especially in the early stages. Although it has been called "juvenile diabetes" due to the frequent onset in children, the majority of individuals living with type 1 diabetes are now adults.
"Brittle" diabetes, also known as unstable diabetes or labile diabetes, is a term that was traditionally used to describe the dramatic and recurrent swings in glucose levels, often occurring for no apparent reason in insulin-dependent diabetes. This term, however, has no biologic basis and should not be used. Still, type 1 diabetes can be accompanied by irregular and unpredictable high blood sugar levels, and the potential for diabetic ketoacidosis or serious low blood sugar levels. Other complications include an impaired counterregulatory response to low blood sugar, infection, gastroparesis (which leads to erratic absorption of dietary carbohydrates), and endocrinopathies (e.g., Addison's disease). These phenomena are believed to occur no more frequently than in 1% to 2% of persons with type 1 diabetes.
Type 1 diabetes is partly inherited, with multiple genes, including certain HLA genotypes, known to influence the risk of diabetes. In genetically susceptible people, the onset of diabetes can be triggered by one or more environmental factors, such as a viral infection or diet. Several viruses have been implicated, but to date there is no stringent evidence to support this hypothesis in humans.
Type 1 diabetes can occur at any age, and a significant proportion is diagnosed during adulthood. Latent autoimmune diabetes of adults (LADA) is the diagnostic term applied when type 1 diabetes develops in adults; it has a slower onset than the same condition in children. Given this difference, some use the unofficial term "type 1.5 diabetes" for this condition. Adults with LADA are frequently initially misdiagnosed as having type 2 diabetes, based on age rather than a cause.
Type 2 diabetes is characterized by insulin resistance, which may be combined with relatively reduced insulin secretion. The defective responsiveness of body tissues to insulin is believed to involve the insulin receptor. However, the specific defects are not known. Diabetes mellitus cases due to a known defect are classified separately. Type 2 diabetes is the most common type of diabetes mellitus accounting for 95% of diabetes. Many people with type 2 diabetes have evidence of prediabetes (impaired fasting glucose and/or impaired glucose tolerance) before meeting the criteria for type 2 diabetes. The progression of prediabetes to overt type 2 diabetes can be slowed or reversed by lifestyle changes or medications that improve insulin sensitivity or reduce the liver's glucose production.
Type 2 diabetes is primarily due to lifestyle factors and genetics. A number of lifestyle factors are known to be important to the development of type 2 diabetes, including obesity (defined by a body mass index of greater than 30), lack of physical activity, poor diet, stress, and urbanization. Excess body fat is associated with 30% of cases in people of Chinese and Japanese descent, 60–80% of cases in those of European and African descent, and 100% of Pima Indians and Pacific Islanders. Even those who are not obese may have a high waist–hip ratio.
Dietary factors such as sugar-sweetened drinks are associated with an increased risk. The type of fats in the diet is also important, with saturated fat and trans fats increasing the risk and polyunsaturated and monounsaturated fat decreasing the risk. Eating white rice excessively may increase the risk of diabetes, especially in Chinese and Japanese people. Lack of physical activity may increase the risk of diabetes in some people.
Adverse childhood experiences, including abuse, neglect, and household difficulties, increase the likelihood of type 2 diabetes later in life by 32%, with neglect having the strongest effect.
Antipsychotic medication side effects (specifically metabolic abnormalities, dyslipidemia and weight gain) and unhealthy lifestyles (including poor diet and decreased physical activity), are potential risk factors.
Gestational diabetes resembles type 2 diabetes in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness. It occurs in about 2–10% of all pregnancies and may improve or disappear after delivery. It is recommended that all pregnant women get tested starting around 24–28 weeks gestation. It is most often diagnosed in the second or third trimester because of the increase in insulin-antagonist hormone levels that occurs at this time. However, after pregnancy approximately 5–10% of women with gestational diabetes are found to have another form of diabetes, most commonly type 2. Gestational diabetes is fully treatable, but requires careful medical supervision throughout the pregnancy. Management may include dietary changes, blood glucose monitoring, and in some cases, insulin may be required.
Though it may be transient, untreated gestational diabetes can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital heart and central nervous system abnormalities, and skeletal muscle malformations. Increased levels of insulin in a fetus's blood may inhibit fetal surfactant production and cause infant respiratory distress syndrome. A high blood bilirubin level may result from red blood cell destruction. In severe cases, perinatal death may occur, most commonly as a result of poor placental perfusion due to vascular impairment. Labor induction may be indicated with decreased placental function. A caesarean section may be performed if there is marked fetal distress or an increased risk of injury associated with macrosomia, such as shoulder dystocia.
Maturity onset diabetes of the young (MODY) is a rare autosomal dominant inherited form of diabetes, due to one of several single-gene mutations causing defects in insulin production. It is significantly less common than the three main types, constituting 1–2% of all cases. The name of this disease refers to early hypotheses as to its nature. Being due to a defective gene, this disease varies in age at presentation and in severity according to the specific gene defect; thus, there are at least 13 subtypes of MODY. People with MODY often can control it without using insulin.
Some cases of diabetes are caused by the body's tissue receptors not responding to insulin (even when insulin levels are normal, which is what separates it from type 2 diabetes); this form is very uncommon. Genetic mutations (autosomal or mitochondrial) can lead to defects in beta cell function. Abnormal insulin action may also have been genetically determined in some cases. Any disease that causes extensive damage to the pancreas may lead to diabetes (for example, chronic pancreatitis and cystic fibrosis). Diseases associated with excessive secretion of insulin-antagonistic hormones can cause diabetes (which is typically resolved once the hormone excess is removed). Many drugs impair insulin secretion and some toxins damage pancreatic beta cells, whereas others increase insulin resistance (especially glucocorticoids which can provoke "steroid diabetes"). The ICD-10 (1992) diagnostic entity, malnutrition-related diabetes mellitus (ICD-10 code E12), was deprecated by the World Health Organization (WHO) when the current taxonomy was introduced in 1999. Yet another form of diabetes that people may develop is double diabetes. This is when a type 1 diabetic becomes insulin resistant, the hallmark for type 2 diabetes or has a family history for type 2 diabetes. It was first discovered in 1990 or 1991.
The following is a list of disorders that may increase the risk of diabetes:
- Genetic defects of β-cell function
- Maturity onset diabetes of the young
- Mitochondrial DNA mutations
- Genetic defects in insulin processing or insulin action
- Defects in proinsulin conversion
- Insulin gene mutations
- Insulin receptor mutations
- Exocrine pancreatic defects (see Type 3c diabetes, i.e. pancreatogenic diabetes)
- Chronic pancreatitis
- Pancreatic neoplasia
- Cystic fibrosis
- Fibrocalculous pancreatopathy
- Growth hormone excess (acromegaly)
- Cushing syndrome
- Cytomegalovirus infection
- Coxsackievirus B
- Thyroid hormone
- β-adrenergic agonists
Insulin is the principal hormone that regulates the uptake of glucose from the blood into most cells of the body, especially liver, adipose tissue and muscle, except smooth muscle, in which insulin acts via the IGF-1. Therefore, deficiency of insulin or the insensitivity of its receptors play a central role in all forms of diabetes mellitus.
The body obtains glucose from three main sources: the intestinal absorption of food; the breakdown of glycogen (glycogenolysis), the storage form of glucose found in the liver; and gluconeogenesis, the generation of glucose from non-carbohydrate substrates in the body. Insulin plays a critical role in regulating glucose levels in the body. Insulin can inhibit the breakdown of glycogen or the process of gluconeogenesis, it can stimulate the transport of glucose into fat and muscle cells, and it can stimulate the storage of glucose in the form of glycogen.
Insulin is released into the blood by beta cells (β-cells), found in the islets of Langerhans in the pancreas, in response to rising levels of blood glucose, typically after eating. Insulin is used by about two-thirds of the body's cells to absorb glucose from the blood for use as fuel, for conversion to other needed molecules, or for storage. Lower glucose levels result in decreased insulin release from the beta cells and in the breakdown of glycogen to glucose. This process is mainly controlled by the hormone glucagon, which acts in the opposite manner to insulin.
If the amount of insulin available is insufficient, or if cells respond poorly to the effects of insulin (insulin resistance), or if the insulin itself is defective, then glucose is not absorbed properly by the body cells that require it, and is not stored appropriately in the liver and muscles. The net effect is persistently high levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as metabolic acidosis in cases of complete insulin deficiency.
When glucose concentration in the blood remains high over time, the kidneys reach a threshold of reabsorption, and the body excretes glucose in the urine (glycosuria). This increases the osmotic pressure of the urine and inhibits reabsorption of water by the kidney, resulting in increased urine production (polyuria) and increased fluid loss. Lost blood volume is replaced osmotically from water in body cells and other body compartments, causing dehydration and increased thirst (polydipsia). In addition, intracellular glucose deficiency stimulates appetite leading to excessive food intake (polyphagia).
Diabetes mellitus is diagnosed with a test for the glucose content in the blood, and is diagnosed by demonstrating any one of the following:
- Fasting plasma glucose level ≥ 7.0 mmol/L (126 mg/dL). For this test, blood is taken after a period of fasting, i.e. in the morning before breakfast, after the patient had sufficient time to fast overnight.
- Plasma glucose ≥ 11.1 mmol/L (200 mg/dL) two hours after a 75 gram oral glucose load as in a glucose tolerance test (OGTT)
- Symptoms of high blood sugar and plasma glucose ≥ 11.1 mmol/L (200 mg/dL) either while fasting or not fasting
- Glycated hemoglobin (HbA1C) ≥ 48 mmol/mol (≥ 6.5 DCCT %).
A positive result, in the absence of unequivocal high blood sugar, should be confirmed by a repeat of any of the above methods on a different day. It is preferable to measure a fasting glucose level because of the ease of measurement and the considerable time commitment of formal glucose tolerance testing, which takes two hours to complete and offers no prognostic advantage over the fasting test. According to the current definition, two fasting glucose measurements above 7.0 mmol/L (126 mg/dL) is considered diagnostic for diabetes mellitus.
Per the WHO, people with fasting glucose levels from 6.1 to 6.9 mmol/L (110 to 125 mg/dL) are considered to have impaired fasting glucose. People with plasma glucose at or above 7.8 mmol/L (140 mg/dL), but not over 11.1 mmol/L (200 mg/dL), two hours after a 75 gram oral glucose load are considered to have impaired glucose tolerance. Of these two prediabetic states, the latter in particular is a major risk factor for progression to full-blown diabetes mellitus, as well as cardiovascular disease. The American Diabetes Association (ADA) since 2003 uses a slightly different range for impaired fasting glucose of 5.6 to 6.9 mmol/L (100 to 125 mg/dL).
Glycated hemoglobin is better than fasting glucose for determining risks of cardiovascular disease and death from any cause.
There is no known preventive measure for type 1 diabetes. Type 2 diabetes—which accounts for 85–90% of all cases worldwide—can often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and eating a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well.
The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.
Diabetes management concentrates on keeping blood sugar levels close to normal, without causing low blood sugar. This can usually be accomplished with dietary changes, exercise, weight loss, and use of appropriate medications (insulin, oral medications).
Learning about the disease and actively participating in the treatment is important, since complications are far less common and less severe in people who have well-managed blood sugar levels. The goal of treatment is an A1C level below 5.7%. Attention is also paid to other health problems that may accelerate the negative effects of diabetes. These include smoking, high blood pressure, metabolic syndrome obesity, and lack of regular exercise. Specialized footwear is widely used to reduce the risk of diabetic foot ulcers by relieving the pressure on the foot. Foot examination for patients living with diabetes should be done annually which includes sensation testing, foot biomechanics, vascular integrity and foot structure.
Concerning those with severe mental illness, the efficacy of type 2 diabetes self-management interventions is still poorly explored, with insufficient scientific evidence to show whether these interventions have similar results to those observed in the general population.
People with diabetes can benefit from education about the disease and treatment, dietary changes, and exercise, with the goal of keeping both short-term and long-term blood glucose levels within acceptable bounds. In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications are recommended to control blood pressure.
Weight loss can prevent progression from prediabetes to diabetes type 2, decrease the risk of cardiovascular disease, or result in a partial remission in people with diabetes. No single dietary pattern is best for all people with diabetes. Healthy dietary patterns, such as the Mediterranean diet, low-carbohydrate diet, or DASH diet, are often recommended, although evidence does not support one over the others. According to the ADA, "reducing overall carbohydrate intake for individuals with diabetes has demonstrated the most evidence for improving glycemia", and for individuals with type 2 diabetes who cannot meet the glycemic targets or where reducing anti-glycemic medications is a priority, low or very-low carbohydrate diets are a viable approach. For overweight people with type 2 diabetes, any diet that achieves weight loss is effective.
Most medications used to treat diabetes act by lowering blood sugar levels through different mechanisms. There is broad consensus that when people with diabetes maintain tight glucose control – keeping the glucose levels in their blood within normal ranges – they experience fewer complications, such as kidney problems or eye problems. There is however debate as to whether this is appropriate and cost effective for people later in life in whom the risk of hypoglycemia may be more significant.
There are a number of different classes of anti-diabetic medications. Type 1 diabetes requires treatment with insulin, ideally using a "basal bolus" regimen that most closely matches normal insulin release: long-acting insulin for the basal rate and short-acting insulin with meals. Type 2 diabetes is generally treated with medication that is taken by mouth (e.g. metformin) although some eventually require injectable treatment with insulin or GLP-1 agonists.
Metformin is generally recommended as a first-line treatment for type 2 diabetes, as there is good evidence that it decreases mortality. It works by decreasing the liver's production of glucose, and increasing the amount of glucose stored in peripheral tissue. Several other groups of drugs, mainly oral medication, may also decrease blood sugar in type 2 diabetes. These include agents that increase insulin release (sulfonylureas), agents that decrease absorption of sugar from the intestines (acarbose), agents that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4) that inactivates incretins such as GLP-1 and GIP (sitagliptin), agents that make the body more sensitive to insulin (thiazolidinedione) and agents that increase the excretion of glucose in the urine (SGLT2 inhibitors). When insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications.
Some severe cases of type 2 diabetes may also be treated with insulin, which is increased gradually until glucose targets are reached.
Blood pressure lowering
Cardiovascular disease is a serious complication associated with diabetes, and many international guidelines recommend blood pressure treatment targets that are lower than 140/90 mmHg for people with diabetes. However, there is only limited evidence regarding what the lower targets should be. A 2016 systematic review found potential harm to treating to targets lower than 140 mmHg, and a subsequent systematic review in 2019 found no evidence of additional benefit from blood pressure lowering to between 130 – 140mmHg, although there was an increased risk of adverse events.
2015 American Diabetes Association recommendations are that people with diabetes and albuminuria should receive an inhibitor of the renin-angiotensin system to reduce the risks of progression to end-stage renal disease, cardiovascular events, and death. There is some evidence that angiotensin converting enzyme inhibitors (ACEIs) are superior to other inhibitors of the renin-angiotensin system such as angiotensin receptor blockers (ARBs), or aliskiren in preventing cardiovascular disease. Although a more recent review found similar effects of ACEIs and ARBs on major cardiovascular and renal outcomes. There is no evidence that combining ACEIs and ARBs provides additional benefits.
The use of aspirin to prevent cardiovascular disease in diabetes is controversial. Aspirin is recommended by some in people at high risk of cardiovascular disease, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes. 2015 American Diabetes Association recommendations for aspirin use (based on expert consensus or clinical experience) are that low-dose aspirin use is reasonable in adults with diabetes who are at intermediate risk of cardiovascular disease (10-year cardiovascular disease risk, 5–10%). National guidelines for England and Wales by the National Institute for Health and Care Excellence (NICE) recommend against the use of aspirin in people with type 1 or type 2 diabetes who do not have confirmed cardiovascular disease.
Weight loss surgery in those with obesity and type 2 diabetes is often an effective measure. Many are able to maintain normal blood sugar levels with little or no medications following surgery and long-term mortality is decreased. There is, however, a short-term mortality risk of less than 1% from the surgery. The body mass index cutoffs for when surgery is appropriate are not yet clear. It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.
A pancreas transplant is occasionally considered for people with type 1 diabetes who have severe complications of their disease, including end stage kidney disease requiring kidney transplantation.
Self-management and support
In countries using a general practitioner system, such as the United Kingdom, care may take place mainly outside hospitals, with hospital-based specialist care used only in case of complications, difficult blood sugar control, or research projects. In other circumstances, general practitioners and specialists share care in a team approach. Home telehealth support can be an effective management technique.
The use of technology to deliver educational programs for adults with type 2 diabetes includes computer-based self-management interventions to collect for tailored responses to facilitate self-management. There is no adequate evidence to support effects on cholesterol, blood pressure, behavioral change (such as physical activity levels and dietary), depression, weight and health-related quality of life, nor in other biological, cognitive or emotional outcomes.
In 2017, 425 million people had diabetes worldwide, up from an estimated 382 million people in 2013 and from 108 million in 1980. Accounting for the shifting age structure of the global population, the prevalence of diabetes is 8.8% among adults, nearly double the rate of 4.7% in 1980. Type 2 makes up about 90% of the cases. Some data indicate rates are roughly equal in women and men, but male excess in diabetes has been found in many populations with higher type 2 incidence, possibly due to sex-related differences in insulin sensitivity, consequences of obesity and regional body fat deposition, and other contributing factors such as high blood pressure, tobacco smoking, and alcohol intake.
The WHO estimates that diabetes resulted in 1.5 million deaths in 2012, making it the 8th leading cause of death. However another 2.2 million deaths worldwide were attributable to high blood glucose and the increased risks of cardiovascular disease and other associated complications (e.g. kidney failure), which often lead to premature death and are often listed as the underlying cause on death certificates rather than diabetes. For example, in 2017, the International Diabetes Federation (IDF) estimated that diabetes resulted in 4.0 million deaths worldwide, using modeling to estimate the total number of deaths that could be directly or indirectly attributed to diabetes.
Diabetes occurs throughout the world but is more common (especially type 2) in more developed countries. The greatest increase in rates has however been seen in low- and middle-income countries, where more than 80% of diabetic deaths occur. The fastest prevalence increase is expected to occur in Asia and Africa, where most people with diabetes will probably live in 2030. The increase in rates in developing countries follows the trend of urbanization and lifestyle changes, including increasingly sedentary lifestyles, less physically demanding work and the global nutrition transition, marked by increased intake of foods that are high energy-dense but nutrient-poor (often high in sugar and saturated fats, sometimes referred to as the "Western-style" diet). The global number of diabetes cases might increase by 48% between 2017 and 2045.
As of 2020, 38% of all US adults had prediabetes. Prediabetes is an early stage of diabetes.
Diabetes was one of the first diseases described, with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine." The Ebers papyrus includes a recommendation for a drink to take in such cases. The first described cases are believed to have been type 1 diabetes. Indian physicians around the same time identified the disease and classified it as madhumeha or "honey urine", noting the urine would attract ants.
The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Apollonius of Memphis. The disease was considered rare during the time of the Roman empire, with Galen commenting he had only seen two cases during his career. This is possibly due to the diet and lifestyle of the ancients, or because the clinical symptoms were observed during the advanced stage of the disease. Galen named the disease "diarrhea of the urine" (diarrhea urinosa).
The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to the moisture and coldness, reflecting the beliefs of the "Pneumatic School". He hypothesized a correlation between diabetes and other diseases, and he discussed differential diagnosis from the snakebite, which also provokes excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.
Two types of diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400–500 CE with one type being associated with youth and another type with being overweight. Effective treatment was not developed until the early part of the 20th century when Canadians Frederick Banting and Charles Herbert Best isolated and purified insulin in 1921 and 1922. This was followed by the development of the long-acting insulin NPH in the 1940s.
The word diabetes (/ˌdaɪ.əˈbiːtiːz/ or /ˌdaɪ.əˈbiːtɪs/) comes from Latin diabētēs, which in turn comes from Ancient Greek διαβήτης (diabētēs), which literally means "a passer through; a siphon". Ancient Greece physician Aretaeus of Cappadocia (fl. 1st century CE) used that word, with the intended meaning "excessive discharge of urine", as the name for the disease. Ultimately, the word comes from Greek διαβαίνειν (diabainein), meaning "to pass through", which is composed of δια- (dia-), meaning "through" and βαίνειν (bainein), meaning "to go". The word "diabetes" is first recorded in English, in the form diabete, in a medical text written around 1425.
The word mellitus (/məˈlaɪtəs/ or /ˈmɛlɪtəs/) comes from the classical Latin word mellītus, meaning "mellite" (i.e. sweetened with honey; honey-sweet). The Latin word comes from mell-, which comes from mel, meaning "honey"; sweetness; pleasant thing, and the suffix -ītus, whose meaning is the same as that of the English suffix "-ite". It was Thomas Willis who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a person with diabetes had a sweet taste (glycosuria). This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, Indians, and Persians .
Society and culture
The 1989 "St. Vincent Declaration" was the result of international efforts to improve the care accorded to those with diabetes. Doing so is important not only in terms of quality of life and life expectancy but also economically – expenses due to diabetes have been shown to be a major drain on health – and productivity-related resources for healthcare systems and governments.
Several countries established more and less successful national diabetes programmes to improve treatment of the disease.
People with diabetes who have neuropathic symptoms such as numbness or tingling in feet or hands are twice as likely to be unemployed as those without the symptoms.
In 2010, diabetes-related emergency room (ER) visit rates in the United States were higher among people from the lowest income communities (526 per 10,000 population) than from the highest income communities (236 per 10,000 population). Approximately 9.4% of diabetes-related ER visits were for the uninsured.
The term "type 1 diabetes" has replaced several former terms, including childhood-onset diabetes, juvenile diabetes, and insulin-dependent diabetes mellitus. Likewise, the term "type 2 diabetes" has replaced several former terms, including adult-onset diabetes, obesity-related diabetes, and noninsulin-dependent diabetes mellitus. Beyond these two types, there is no agreed-upon standard nomenclature.
Diabetes mellitus is also occasionally known as "sugar diabetes" to differentiate it from diabetes insipidus.
Diabetes can occur in mammals or reptiles. Birds do not develop diabetes because of their unusually high tolerance for elevated blood glucose levels.
In animals, diabetes is most commonly encountered in dogs and cats. Middle-aged animals are most commonly affected. Female dogs are twice as likely to be affected as males, while according to some sources, male cats are more prone than females. In both species, all breeds may be affected, but some small dog breeds are particularly likely to develop diabetes, such as Miniature Poodles.
Feline diabetes is strikingly similar to human type 2 diabetes. The Burmese, Russian Blue, Abyssinian, and Norwegian Forest cat breeds are at higher risk than other breeds. Overweight cats are also at higher risk.
The symptoms may relate to fluid loss and polyuria, but the course may also be insidious. Diabetic animals are more prone to infections. The long-term complications recognized in humans are much rarer in animals. The principles of treatment (weight loss, oral antidiabetics, subcutaneous insulin) and management of emergencies (e.g. ketoacidosis) are similar to those in humans.
- ↑ "Diabetes Blue Circle Symbol". International Diabetes Federation. 17 March 2006. http://www.diabetesbluecircle.org.
- ↑ 2.0 2.1 2.2 "IDF DIABETES ATLAS Ninth Edition 2019" (in EN). https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf.
- ↑ 3.0 3.1 "Diabetes". https://www.who.int/health-topics/diabetes.
- ↑ "Diabetes Mellitus (DM) - Hormonal and Metabolic Disorders". https://www.msdmanuals.com/en-gb/home/hormonal-and-metabolic-disorders/diabetes-mellitus-dm-and-disorders-of-blood-sugar-metabolism/diabetes-mellitus-dm.
- ↑ 5.0 5.1 5.2 5.3 "Chapter 17". Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. 2011. ISBN 978-0-07-162243-1.
- ↑ 6.0 6.1 6.2 "Hyperglycemic crises in adult patients with diabetes". Diabetes Care 32 (7): 1335–1343. July 2009. doi:10.2337/dc09-9032. PMID 19564476. PMC 2699725. http://care.diabetesjournals.org/content/32/7/1335.full.
- ↑ "Inequalities in the prevalence of diabetes mellitus and its risk factors in Sri Lanka: a lower middle income country". International Journal for Equity in Health 17 (1): 45. April 2018. doi:10.1186/s12939-018-0759-3. PMID 29665834.
- ↑ 8.0 8.1 8.2 "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2163–2196. December 2012. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
- ↑ "The top 10 causes of death" (in en). https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- ↑ "Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030". Diabetes Care 41 (5): 963–970. May 2018. doi:10.2337/dc17-1962. PMID 29475843.
- ↑ "Type 1 diabetes mellitus in pediatrics". Pediatrics in Review 29 (11): 374–84; quiz 385. November 2008. doi:10.1542/pir.29-11-374. PMID 18977856.
- ↑ "WHO | Diabetes mellitus". https://www.who.int/mediacentre/factsheets/fs138/en/.
- ↑ (in en) Diabetes: Symptoms, Causes, Treatment and Prevention. 2015. ISBN 978-1-5146-0305-5. https://books.google.com/books?id=WpbVCwAAQBAJ&pg=PP6.
- ↑ "When hypoglycemia is not obvious: diagnosing and treating under-recognized and undisclosed hypoglycemia". Primary Care Diabetes 8 (1): 3–11. April 2014. doi:10.1016/j.pcd.2013.09.002. PMID 24100231.
- ↑ "Seizures and type 1 diabetes mellitus: current state of knowledge". European Journal of Endocrinology 167 (6): 749–758. December 2012. doi:10.1530/EJE-12-0699. PMID 22956556.
- ↑ "Symptoms of Low Blood Sugar". http://www.webmd.com/a-to-z-guides/symptoms-of-low-blood-sugar-topic-overview.
- ↑ "Glucagon–Injection side effects, medical uses, and drug interactions." (in en). MedicineNet. https://www.medicinenet.com/glucagon-injection/article.htm.
- ↑ "Diabetes - long-term effects". https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/diabetes-long-term-effects.
- ↑ "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies". Lancet 375 (9733): 2215–2222. June 2010. doi:10.1016/S0140-6736(10)60484-9. PMID 20609967.
- ↑ "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation 127 (4): e362–e425. January 2013. doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304.
- ↑ "Complications of Diabetes 2017". Journal of Diabetes Research 2018: 3086167. 11 March 2018. doi:10.1155/2018/3086167. PMID 29713648.
- ↑ "Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021". Preventing Chronic Disease (Centers for Disease Control and Prevention) 18: E66. July 2021. doi:10.5888/pcd18.210123. PMID 34197283.
- ↑ 23.0 23.1 23.2 23.3 "Diabetes Programme". World Health Organization. https://www.who.int/diabetes/action_online/basics/en/index3.html.
- ↑ "Diabetes – eye care: MedlinePlus Medical Encyclopedia" (in en). https://medlineplus.gov/ency/patientinstructions/000078.htm.
- ↑ "Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies". Diabetologia 48 (12): 2460–2469. December 2005. doi:10.1007/s00125-005-0023-4. PMID 16283246.
- ↑ "Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis". Age and Ageing 45 (6): 761–767. November 2016. doi:10.1093/ageing/afw140. PMID 27515679.
- ↑ 27.0 27.1 27.2 Williams textbook of endocrinology (12th ed.). Elsevier/Saunders. 2011. pp. 1371–1435. ISBN 978-1-4377-0324-5.
- ↑ "What is Type 1 Diabetes?". Medicine 30: 1–5. 2002. doi:10.1383/medc.184.108.40.206264.
- ↑ "Co-aggregation and heritability of organ-specific autoimmunity: a population-based twin study". European Journal of Endocrinology 182 (5): 473–480. May 2020. doi:10.1530/EJE-20-0049. PMID 32229696.
- ↑ "Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study". Diabetes 52 (4): 1052–1055. April 2003. doi:10.2337/diabetes.52.4.1052. PMID 12663480.
- ↑ "A study of diabetes mellitus within a large sample of Australian twins". Twin Research and Human Genetics 11 (1): 28–40. February 2008. doi:10.1375/twin.11.1.28. PMID 18251672. https://www.pure.ed.ac.uk/ws/files/11913813/study_of_diabetes_mellitus_within_a_large_sample_of_Australian_twins.pdf.
- ↑ "The Concordance and Heritability of Type 2 Diabetes in 34,166 Twin Pairs From International Twin Registers: The Discordant Twin (DISCOTWIN) Consortium". Twin Research and Human Genetics 18 (6): 762–771. December 2015. doi:10.1017/thg.2015.83. PMID 26678054.
- ↑ "Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis". Health Promotion Perspectives 10 (2): 98–115. 2020-03-30. doi:10.34172/hpp.2020.18. PMID 32296622.
- ↑ "Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025". Scientific Reports 10 (1): 14790. September 2020. doi:10.1038/s41598-020-71908-9. PMID 32901098. Bibcode: 2020NatSR..1014790L.
- ↑ "An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective". Endocrinology and Metabolism Clinics of North America 50 (3): 337–355. September 2021. doi:10.1016/j.ecl.2021.05.013. PMID 34399949.
- ↑ "Classification of Diabetes mellitus 2019" (in en). https://apps.who.int/iris/rest/bitstreams/1233344/retrieve.
- ↑ "The many faces of diabetes: a disease with increasing heterogeneity". Lancet 383 (9922): 1084–1094. March 2014. doi:10.1016/S0140-6736(13)62219-9. PMID 24315621.
- ↑ "Diabetes treatment--bridging the divide". The New England Journal of Medicine 356 (15): 1499–1501. April 2007. doi:10.1056/NEJMp078030. PMID 17429082.
- ↑ "Type 1 diabetes through the life span: a position statement of the American Diabetes Association". Diabetes Care 37 (7): 2034–2054. July 2014. doi:10.2337/dc14-1140. PMID 24935775.
- ↑ 40.0 40.1 "Diabetes Mellitus (DM): Diabetes Mellitus and Disorders of Carbohydrate Metabolism: Merck Manual Professional". Merck Publishing. April 2010. http://www.merck.com/mmpe/sec12/ch158/ch158b.html#sec12-ch158-ch158b-1206.
- ↑ "[Essential labile diabetes (author's transl)]" (in de). Munchener Medizinische Wochenschrift 119 (19): 671–674. May 1977. PMID 406527.
- ↑ 42.0 42.1 "Mechanisms of Beta Cell Dysfunction Associated With Viral Infection". Current Diabetes Reports 15 (10): 73. October 2015. doi:10.1007/s11892-015-0654-x. PMID 26280364. "So far, none of the hypotheses accounting for virus-induced beta cell autoimmunity has been supported by stringent evidence in humans, and the involvement of several mechanisms rather than just one is also plausible.".
- ↑ "Environmental Risk Factors and Type 1 Diabetes: Past, Present, and Future". Canadian Journal of Diabetes 40 (6): 586–593. December 2016. doi:10.1016/j.jcjd.2016.05.002. PMID 27545597.
- ↑ "Latent autoimmune diabetes of the adult: current knowledge and uncertainty". Diabetic Medicine 32 (7): 843–852. July 2015. doi:10.1111/dme.12700. PMID 25601320.
- ↑ 45.0 45.1 45.2 Cite error: Invalid
<ref>tag; no text was provided for refs named
- ↑ American Diabetes Association (January 2017). "2. Classification and Diagnosis of Diabetes". Diabetes Care 40 (Suppl 1): S11–S24. doi:10.2337/dc17-S005. PMID 27979889.
- ↑ "Prevention of Diabetes Mellitus in Patients With Prediabetes". The American Journal of Cardiology 123 (3): 507–512. February 2019. doi:10.1016/j.amjcard.2018.10.032. PMID 30528418.
- ↑ 48.0 48.1 "Dietary fats and prevention of type 2 diabetes". Progress in Lipid Research 48 (1): 44–51. January 2009. doi:10.1016/j.plipres.2008.10.002. PMID 19032965.
- ↑ "Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk". Circulation 121 (11): 1356–1364. March 2010. doi:10.1161/CIRCULATIONAHA.109.876185. PMID 20308626.
- ↑ "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis". Diabetes Care 33 (11): 2477–2483. November 2010. doi:10.2337/dc10-1079. PMID 20693348.
- ↑ "White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review". BMJ 344: e1454. March 2012. doi:10.1136/bmj.e1454. PMID 22422870.
- ↑ "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". Lancet 380 (9838): 219–229. July 2012. doi:10.1016/S0140-6736(12)61031-9. PMID 22818936.
- ↑ "Adverse childhood experiences and risk of type 2 diabetes: A systematic review and meta-analysis". Metabolism 64 (11): 1408–1418. November 2015. doi:10.1016/j.metabol.2015.08.019. PMID 26404480.
- ↑ "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis". BMC Psychiatry 17 (1): 373. November 2017. doi:10.1186/s12888-017-1539-0. PMID 29162032.
- ↑ 55.0 55.1 "National Diabetes Clearinghouse (NDIC): National Diabetes Statistics 2011". U.S. Department of Health and Human Services. http://diabetes.niddk.nih.gov/dm/pubs/statistics/#Gestational.
- ↑ 56.0 56.1 "Krause's Food & The Nutrition Care Process". Journal of Nutrition Education and Behavior 51 (10): 1225. November 2019. doi:10.1016/j.jneb.2019.06.022. ISSN 1499-4046.
- ↑ "Managing & Treating Gestational Diabetes | NIDDK" (in en-US). https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational/management-treatment.
- ↑ "Intrapartal cardiotocographic patterns and hypoxia-related perinatal outcomes in pregnancies complicated by gestational diabetes mellitus". Acta Diabetologica 58 (11): 1563–1573. November 2021. doi:10.1007/s00592-021-01756-0. PMID 34151398.
- ↑ National Collaborating Centre for Women's and Children's Health (February 2015). "Intrapartum care" (in en). Diabetes in Pregnancy: Management of diabetes and its complications from preconception to the postnatal period. National Institute for Health and Care Excellence (UK). https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0080685/.
- ↑ "Monogenic Forms of Diabetes". US NIH. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/monogenic-neonatal-mellitus-mody#3.
- ↑ "Diagnosis and management of maturity onset diabetes of the young (MODY)". BMJ 343 (oct19 3): d6044. October 2011. doi:10.1136/bmj.d6044. PMID 22012810.
- ↑ 62.0 62.1 "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications". World Health Organization. 1999. http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf.
- ↑ "Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?". Diabetologia (National Library of Medicine) 56 (7): 1462–1470. July 2013. doi:10.1007/s00125-013-2904-2. PMID 23613085.
- ↑ Unless otherwise specified, reference is: Table 20-5 in Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007). Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN 978-1-4160-2973-1.
- ↑ "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet 375 (9716): 735–742. February 2010. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
- ↑ "Insulin Basics". American Diabetes Association. http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/insulin-basics.html.
- ↑ 67.0 67.1 67.2 67.3 Greenspan's basic & clinical endocrinology (9th ed.). McGraw-Hill Medical. 2011. ISBN 978-0-07-162243-1.
- ↑ Ganong's review of medical physiology (24th ed.). McGraw-Hill Medical. 2012. ISBN 978-0-07-178003-2.
- ↑ Harper's illustrated biochemistry (29th ed.). McGraw-Hill Medical. 2012. ISBN 978-0-07-176576-3.
- ↑ Juta's Complete Textbook of Medical Surgical Nursing. Cape Town: Juta. 2013. pp. 839.
- ↑ "Summary of revisions for the 2010 Clinical Practice Recommendations". Diabetes Care 33 (Suppl 1): S3. January 2010. doi:10.2337/dc10-S003. PMID 20042773. PMC 2797388. http://care.diabetesjournals.org/content/33/Supplement_1/S3.full. Retrieved 29 January 2010.
- ↑ "Postchallenge hyperglycemia and mortality in a national sample of U.S. adults". Diabetes Care 24 (8): 1397–1402. August 2001. doi:10.2337/diacare.24.8.1397. PMID 11473076.
- ↑ Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization. 2006. p. 21. ISBN 978-92-4-159493-6. https://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf.
- ↑ "Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose". Evidence Report/Technology Assessment (Agency for Healthcare Research and Quality) (128): 1–11. August 2005. PMID 16194123. PMC 4780988. http://www.ahrq.gov/clinic/epcsums/impglusum.htm. Retrieved 20 July 2008.
- ↑ "The oral glucose tolerance test (OGTT) revisited". European Journal of Internal Medicine 22 (1): 8–12. February 2011. doi:10.1016/j.ejim.2010.07.008. PMID 21238885.
- ↑ "Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults". The New England Journal of Medicine 362 (9): 800–811. March 2010. doi:10.1056/NEJMoa0908359. PMID 20200384.
- ↑ "Tackling risk factors for type 2 diabetes in adolescents: PRE-STARt study in Euskadi". Anales de Pediatria (Anales de Pediatría) 95 (3): 186–196. 2020. doi:10.1016/j.anpedi.2020.11.001. PMID 33388268.
- ↑ "Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013". BMJ 354: i3857. August 2016. doi:10.1136/bmj.i3857. PMID 27510511.
- ↑ 79.0 79.1 "Simple Steps to Preventing Diabetes". Harvard T.H. Chan School of Public Health. 18 September 2012. http://www.hsph.harvard.edu/nutritionsource/preventing-diabetes-full-story/#references.
- ↑ "Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis". JAMA 298 (22): 2654–2664. December 2007. doi:10.1001/jama.298.22.2654. PMID 18073361.
- ↑ "Chronic diseases and their common risk factors". World Health Organization. 2005. https://www.who.int/chp/chronic_disease_report/media/Factsheet1.pdf.
- ↑ 82.0 82.1 82.2 82.3 "Managing diabetes". National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health. 1 December 2016. https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes.
- ↑ "Effectiveness of plant-based diets in promoting well-being in the management of type 2 diabetes: a systematic review". BMJ Open Diabetes Research & Care 6 (1): e000534. 2018-10-30. doi:10.1136/bmjdrc-2018-000534. PMID 30487971.
- ↑ The Diabetes Control and Complications Trial Research Group (April 1995). "The effect of intensive diabetes therapy on the development and progression of neuropathy". Annals of Internal Medicine 122 (8): 561–568. doi:10.7326/0003-4819-122-8-199504150-00001. PMID 7887548.
- ↑ "The A1C test and diabetes". National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health. 1 April 2018. https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test.
- ↑ "Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians". Annals of Internal Medicine 168 (8): 569–576. April 2018. doi:10.7326/M17-0939. PMID 29507945.
- ↑ National Institute for Health and Clinical Excellence. Clinical guideline 66: Type 2 diabetes. London, 2008.
- ↑ "Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review". Diabetes/Metabolism Research and Reviews 32 (Suppl 1): 99–118. January 2016. doi:10.1002/dmrr.2702. PMID 26342178.
- ↑ "Effectiveness of offloading methods in preventing primary diabetic foot ulcers in adults with diabetes: a systematic review". JBI Database of Systematic Reviews and Implementation Reports 14 (7): 236–265. July 2016. doi:10.11124/JBISRIR-2016-003013. PMID 27532798.
- ↑ "Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review". Diabetes/Metabolism Research and Reviews 36 (S1 Suppl 1): e3270. March 2020. doi:10.1002/dmrr.3270. PMID 31957213. https://eprints.qut.edu.au/220879/1/Van%2BNetten%2Bet%2Bal%2B-%2B2016%2B-%2BPrevention%2Bof%2Bfoot%2Bulcers%2Bsystematic%2Breview.pdf.
- ↑ "Preventive foot care in diabetes". Diabetes Care 27 (suppl_1): S63–S64. January 2004. doi:10.2337/diacare.27.2007.S63. PMID 14693928.
- ↑ "Self management interventions for type 2 diabetes in adult people with severe mental illness". The Cochrane Database of Systematic Reviews 4: CD011361. April 2016. doi:10.1002/14651858.CD011361.pub2. PMID 27120555.
- ↑ "Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials". JAMA Internal Medicine 177 (12): 1808–1817. December 2017. doi:10.1001/jamainternmed.2017.6040. PMID 29114778.
- ↑ "Weight Management in Patients with Type 1 Diabetes and Obesity". Current Diabetes Reports 17 (10): 92. August 2017. doi:10.1007/s11892-017-0918-8. PMID 28836234.
- ↑ 95.0 95.1 American Diabetes Association (January 2019). "5. Lifestyle Management: Standards of Medical Care in Diabetes-2019". Diabetes Care 42 (Suppl 1): S46–S60. doi:10.2337/dc19-S005. PMID 30559231.
- ↑ 96.0 96.1 96.2 "Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report". Diabetes Care 42 (5): 731–754. May 2019. doi:10.2337/dci19-0014. PMID 31000505.
- ↑ 97.0 97.1 "The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups". The British Journal of Nutrition 114 (10): 1656–1666. November 2015. doi:10.1017/S0007114515003475. PMID 26411958.
- ↑ "Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action". Current Obesity Reports 4 (2): 287–302. June 2015. doi:10.1007/s13679-015-0155-x. PMID 26627223.
- ↑ "Diabetic retinopathy: current concepts and emerging therapy". Endocrinology and Metabolism Clinics of North America 42 (4): 721–745. December 2013. doi:10.1016/j.ecl.2013.08.001. PMID 24286948.
- ↑ "Glycemic Control as Primary Prevention for Diabetic Kidney Disease". Advances in Chronic Kidney Disease 25 (2): 141–148. March 2018. doi:10.1053/j.ackd.2017.11.003. PMID 29580578.
- ↑ "One size does not fit all glycemic targets for type 2 diabetes". Journal of Diabetes Investigation 5 (2): 134–141. March 2014. doi:10.1111/jdi.12206. PMID 24843750.
- ↑ 102.0 102.1 "Type 1 diabetes in adults: diagnosis and management". National Institute for Health and Care Excellence. 26 August 2015. https://www.nice.org.uk/guidance/ng17.
- ↑ 103.0 103.1 "Type 2 diabetes in adults: management". National Institute for Health and Care Excellence. 2 December 2015. https://www.nice.org.uk/guidance/ng28.
- ↑ 104.0 104.1 104.2 "Management of blood glucose in type 2 diabetes mellitus". American Family Physician 79 (1): 29–36. January 2009. PMID 19145963. http://www.aafp.org/afp/2009/0101/p29.pdf.
- ↑ 105.0 105.1 "Oral antidiabetic agents: current role in type 2 diabetes mellitus". Drugs 65 (3): 385–411. 2005. doi:10.2165/00003495-200565030-00005. PMID 15669880.
- ↑ Consumer Reports; American College of Physicians (April 2012), "Choosing a type 2 diabetes drug – Why the best first choice is often the oldest drug", High Value Care (Consumer Reports), http://consumerhealthchoices.org/wp-content/uploads/2012/04/High-Value-Care-Diabetes-ACP.pdf, retrieved August 14, 2012
- ↑ "A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes". Global Heart 14 (3): 215–240. September 2019. doi:10.1016/j.gheart.2019.07.009. PMID 31451236.
- ↑ "Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses". BMJ 352: i717. February 2016. doi:10.1136/bmj.i717. PMID 26920333.
- ↑ "Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials". BMJ Open 9 (9): e026686. September 2019. doi:10.1136/bmjopen-2018-026686. PMID 31575567.
- ↑ 110.0 110.1 110.2 "Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association". Diabetes Care 38 (9): 1777–1803. September 2015. doi:10.2337/dci15-0012. PMID 26246459.
- ↑ "Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis". JAMA Internal Medicine 174 (5): 773–785. May 2014. doi:10.1001/jamainternmed.2014.348. PMID 24687000.
- ↑ "Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients". Diabetes & Vascular Disease Research 14 (5): 400–406. September 2017. doi:10.1177/1479164117715854. PMID 28844155.
- ↑ 113.0 113.1 "Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses". PLOS Medicine 13 (3): e1001971. March 2016. doi:10.1371/journal.pmed.1001971. PMID 26954482.
- ↑ "Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation". Diabetes Care 33 (6): 1395–1402. June 2010. doi:10.2337/dc10-0555. PMID 20508233.
- ↑ "The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation". Health Technology Assessment 13 (41): 1–190, 215–357, iii–iv. September 2009. doi:10.3310/hta13410. PMID 19726018.
- ↑ "Bariatric surgery for diabetes management". Current Opinion in Endocrinology, Diabetes and Obesity 16 (2): 119–124. April 2009. doi:10.1097/MED.0b013e32832912e7. PMID 19276974.
- ↑ 117.0 117.1 ""Metabolic" surgery for treatment of type 2 diabetes mellitus". Endocrine Practice 15 (6): 624–631. September–October 2009. doi:10.4158/EP09170.RAR. PMID 19625245.
- ↑ "Bariatric surgery in patients with type 2 diabetes: a viable option". Postgraduate Medicine 123 (1): 24–33. January 2011. doi:10.3810/pgm.2011.01.2242. PMID 21293081.
- ↑ "Bariatric surgery for type 2 diabetes". Lancet 379 (9833): 2300–2311. June 2012. doi:10.1016/S0140-6736(12)60401-2. PMID 22683132.
- ↑ "Pancreas Transplantation". American Diabetes Association. http://www.diabetes.org/living-with-diabetes/treatment-and-care/transplantation/pancreas-transplantation.html.
- ↑ "Home telehealth for diabetes management: a systematic review and meta-analysis". Diabetes, Obesity & Metabolism 11 (10): 913–930. October 2009. doi:10.1111/j.1463-1326.2009.01057.x. PMID 19531058.
- ↑ 122.0 122.1 "Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews 2013 (3): CD008776. March 2013. doi:10.1002/14651858.CD008776.pub2. PMID 23543567.
- ↑ "Computer-assisted versus oral-and-written dietary history taking for diabetes mellitus". The Cochrane Database of Systematic Reviews 2011 (12): CD008488. December 2011. doi:10.1002/14651858.CD008488.pub2. PMID 22161430.
- ↑ 124.0 124.1 124.2 124.3 124.4 Estimated number diabetics worldwide. 10 December 2019. https://www.statista.com/statistics/271442/number-of-diabetics-worldwide/.
- ↑ "The global implications of diabetes and cancer". Lancet 383 (9933): 1947–1948. June 2014. doi:10.1016/S0140-6736(14)60886-2. PMID 24910221.
- ↑ 126.0 126.1 126.2 126.3 126.4 126.5 "Global Report on Diabetes". World Health Organization. 2016. http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf.
- ↑ "Diabetes and gender". Diabetologia 44 (1): 3–15. January 2001. doi:10.1007/s001250051573. PMID 11206408.
- ↑ "Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study". Archives of Internal Medicine 162 (1): 82–89. January 2002. doi:10.1001/archinte.162.1.82. PMID 11784224.
- ↑ "The top 10 causes of death Fact sheet N°310". World Health Organization. October 2013. https://www.who.int/mediacentre/factsheets/fs310/en/.
- ↑ Public Health Agency of Canada, Diabetes in Canada: Facts and figures from a public health perspective. Ottawa, 2011.
- ↑ "Projections of global mortality and burden of disease from 2002 to 2030". PLOS Medicine 3 (11): e442. November 2006. doi:10.1371/journal.pmed.0030442. PMID 17132052.
- ↑ 132.0 132.1 "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030". Diabetes Care 27 (5): 1047–1053. May 2004. doi:10.2337/diacare.27.5.1047. PMID 15111519.
- ↑ "Prevalence of Prediabetes Among Adults - Diabetes". 2018-03-13. https://www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html.
- ↑ Exercise and disease management (2nd ed.). Boca Raton: CRC Press. 2011-04-25. p. 25. ISBN 978-1-4398-2759-8. https://books.google.com/books?id=eAn9-bm_pi8C&pg=PA25.
- ↑ 135.0 135.1 135.2 135.3 135.4 135.5 135.6 135.7 Principles of diabetes mellitus (2nd ed.). New York: Springer. 2009. p. 3. ISBN 978-0-387-09840-1. https://books.google.com/books?id=i0qojvF1SpUC&pg=PA3.
- ↑ 136.0 136.1 "Sickening sweet". Distillations 1 (4): 12–15. 2015. https://www.sciencehistory.org/distillations/magazine/sickening-sweet. Retrieved 20 March 2018.
- ↑ 137.0 137.1 "Aretaeus of Cappadocia and the first description of diabetes". Hormones 11 (1): 109–113. 2012. doi:10.1007/BF03401545. PMID 22450352. http://www.hormones.gr/pdf/HORMONES%202012,%20109-113.pdf.
- ↑ 138.0 138.1 Oxford English Dictionary. diabetes. Retrieved 2011-06-10.
- ↑ 139.0 139.1 "Online Etymology Dictionary. diabetes.". 2001–2010. http://www.etymonline.com/index.php?search=diabetes&searchmode=none.
- ↑ Aretaeus, De causis et signis acutorum morborum (lib. 2), Κεφ. β. περὶ Διαβήτεω (Chapter 2, On Diabetes, Greek original) , on Perseus
- ↑ 141.0 141.1 141.2 141.3 Oxford English Dictionary. mellite. Retrieved 2011-06-10.
- ↑ 142.0 142.1 142.2 142.3 "MyEtimology. mellitus.". http://www.myetymology.com/latin/mellitus.html.
- ↑ Oxford English Dictionary. -ite. Retrieved 2011-06-10.
- ↑ The New Public Health, Second Edition. New York: Academic Press. 2008. p. 200. ISBN 978-0-12-370890-8.
- ↑ "Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee". Diabetic Medicine 10 (4): 371–377. May 1993. doi:10.1111/j.1464-5491.1993.tb00083.x. PMID 8508624.
- ↑ "Type 2 diabetes programmes in Europe". Euro Observer 7 (2): 5–6. 2005. http://www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/euroObserver/Obsvol7no2.pdf.
- ↑ "Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce". Journal of Occupational and Environmental Medicine 49 (6): 672–679. June 2007. doi:10.1097/JOM.0b013e318065b83a. PMID 17563611.
- ↑ Washington R.E.; Andrews R.M.; Mutter R.L. (November 2013). Emergency Department Visits for Adults with Diabetes, 2010. Rockville MD: Agency for Healthcare Research and Quality. PMID 24455787. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb167.jsp.
- ↑ "Type 1 vs. Type 2 Diabetes Differences: Which One Is Worse?" (in en). https://www.medicinenet.com/type_1_vs_type_2_diabetes_similarities_differences/article.htm.
- ↑ Living with diabetes. New York: Facts On File. 2008. p. 143. ISBN 978-1-4381-2108-6. https://archive.org/details/livingwithdiabet0000park.
- ↑ "Comparative occurrence of diabetes in canine, feline, and few wild animals and their association with pancreatic diseases and ketoacidosis with therapeutic approach". Veterinary World 11 (4): 410–422. April 2018. doi:10.14202/vetworld.2018.410-422. PMID 29805204.
- ↑ "Chapter 58 - Hyperglycemia in Reptiles" (in en). Reptile Medicine and Surgery (Second ed.). Saint Louis: W.B. Saunders. 2006-01-01. pp. 822–830. doi:10.1016/b0-72-169327-x/50062-6. ISBN 978-0-7216-9327-9.
- ↑ "Revisiting glucose regulation in birds - A negative model of diabetes complications". Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology 262: 110778. 8 July 2022. doi:10.1016/j.cbpb.2022.110778. PMID 35817273.
- ↑ 154.0 154.1 "Diabetes mellitus". 2005. http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/40302.htm.
- ↑ Feline diabetes mellitus Aspects on epidemiology and pathogenesis. Acta Universitatis agriculturae Sueciae. ISBN 978-91-7760-067-1. https://pub.epsilon.slu.se/14746/1/ohlund_m_171123.pdf.
- American Diabetes Association
- IDF Diabetes Atlas
- National Diabetes Education Program
- ADA's Standards of Medical Care in Diabetes 2019
- "The past 200 years in diabetes". The New England Journal of Medicine 367 (14): 1332–1340. October 2012. doi:10.1056/NEJMra1110560. PMID 23034021.
- "Diabetes". MedlinePlus. U.S. National Library of Medicine. https://medlineplus.gov/diabetes.html.
Original source: https://en.wikipedia.org/wiki/Diabetes. Read more